We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 1 of 1 for:    TIME-2b
Previous Study | Return to List | Next Study

The TIME-2b Study: A Study of AKB-9778, a Novel Tie 2 Activator, in Patients With Non-Proliferative Diabetic Retinopathy (NPDR) (TIME-2b)

This study is currently recruiting participants.
Verified August 2017 by Aerpio Therapeutics
Sponsor:
ClinicalTrials.gov Identifier:
NCT03197870
First Posted: June 23, 2017
Last Update Posted: August 25, 2017
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
Information provided by (Responsible Party):
Aerpio Therapeutics
  Purpose
The purpose of this study is to evaluate the safety and efficacy of subcutaneously administered AKB-9778 15mg once daily or 15mg twice daily for 12 months in patients with moderate to severe non-proliferative diabetic retinopathy (NPDR).

Condition Intervention Phase
Nonproliferative Diabetic Retinopathy Drug: AKB-9778 Drug: Placebo Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: Phase 2 Double-Masked, Placebo-Controlled Study to Assess the Safety and Efficacy of Subcutaneously Administered AKB-9778 15mg Once Daily or 15mg Twice Daily for 12 Months in Patients With Moderate to Severe Non-Proliferative Diabetic Retinopathy

Resource links provided by NLM:


Further study details as provided by Aerpio Therapeutics:

Primary Outcome Measures:
  • Percentage of subjects with an improvement in study eye severity of diabetic retinopathy (DR) (ETDRS DR Severity Score or DRSS) of ≥ 2 steps [ Time Frame: Baseline to Week 48 ]

Secondary Outcome Measures:
  • Secondary outcomes include improvement of DRSS and worsening of DRSS in the study eye, the fellow eye, and both eyes [ Time Frame: Baseline to Week 48 ]
  • Incidence and severity of adverse events [ Time Frame: Baseline to Week 48 ]
  • Change from baseline in clinical laboratory assay results [ Time Frame: Baseline to Week 48 ]

Estimated Enrollment: 150
Actual Study Start Date: June 29, 2017
Estimated Study Completion Date: June 2019
Estimated Primary Completion Date: May 2019 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: AKB-9778 15mg BID Drug: AKB-9778
Subcutaneous AKB-9778 15mg
Experimental: AKB-9778 15mg QD Drug: AKB-9778
Subcutaneous AKB-9778 15mg
Drug: Placebo
Subcutaneous Placebo
Placebo Comparator: Placebo BID Drug: Placebo
Subcutaneous Placebo

  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years to 80 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Key Inclusion Criteria:

  • Adults 18 through 80 years of age (inclusive)
  • Subjects with moderate to very severe NPDR (ETDRS Level 43 - 53 inclusive)
  • No evidence of central involved DME
  • ETDRS BCVA letter score ≥ 70 (Snellen 20/40 or better)

Key Exclusion Criteria:

  • Ocular disease other than DR that may cause substantial reduction in visual acuity, including iris neovascularization, retinal detachment, visually significant epiretinal membrane, vitreous hemorrhage or fibrosis, ocular inflammation (uveitis), other retinal inflammatory or infectious diseases
  • Evidence of neovascularization on clinical examination or imaging
  • Hemoglobin A1C (HbA1C) ≥ 12.0% at Screening
  • Severe acute or chronic medical or psychiatric condition or laboratory abnormality that may increase the risk associated with study participation
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03197870


Contacts
Contact: Steve Pakola, MD (914) 309-3406 spakola@aerpio.com
Contact: Barbara Withers, PhD (513) 256-3592 bwithers@aerpio.com

  Show 42 Study Locations
Sponsors and Collaborators
Aerpio Therapeutics
  More Information

Responsible Party: Aerpio Therapeutics
ClinicalTrials.gov Identifier: NCT03197870     History of Changes
Other Study ID Numbers: AKB-9778-CI-5001
First Submitted: June 22, 2017
First Posted: June 23, 2017
Last Update Posted: August 25, 2017
Last Verified: August 2017
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No

Additional relevant MeSH terms:
Retinal Diseases
Diabetic Retinopathy
Eye Diseases
Diabetic Angiopathies
Vascular Diseases
Cardiovascular Diseases
Diabetes Complications
Diabetes Mellitus
Endocrine System Diseases